At AD/PD 2026, Roche announced that patients treated with prasinezumab for five years demonstrated a sustained slowing of ...
Initial results from the Phase 1b clinical trial in people with Parkinson’s disease demonstrated central nervous system target engagement, a reduction to baseline levels in the prespecified endpoint ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results